Moreover, pLG72 or DAO activator was increased in patients with early-phase dementia with the highest level at mild AD, while it was decreased with the severity of cognitive decline in later-phase AD, indirectly supporting the hypothesis of hypo-NMDAR in early-phase AD and glutamate excitotoxicity in late-phase AD [56]. This evidence concerns the gene DAO and Alzheimer disease.